NCT06575933 2026-02-11
MK-1084-009
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
3 trialsNCT05926180 2024-12-13
Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)
Dizal Pharmaceuticals
Phase 1 Completed
NCT00281021 2018-03-29
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
University of Louisville
Phase 2 Terminated